The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Micromet Inc.  (MITI) Trade Now »     Rate MITI  -  Discuss MITI  -  Add to Watch List         Graphic_subscribe

  
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
77.0%
Top:
100.0%
Rate MITI:



MITI Analysis & Videos »


MITI: Bull or Bear?

FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX Graphic_rating_buy MITI
Mikerun
73%
 +44.04%
in 166 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-s...
By  Mike Havrilla   (+1.04%  risk: conservative)  06/08/09 Comment


Micromet to Trade with Biotechs MITI
+167.04%
in 520 days
In the absence of significant company news, we believe the stock will move in sentiment with the broader biotech sector
By  Zacks.com   (-14.38%  risk: moderate)  06/18/08 Comment


Micromet Exceeds Expectations, Again Graphic_rating_buy MITI
+172.14%
in 532 days

In an industry where most companies over-promise and under-deliver, a company that exceeds even the most optimistic expectations is a unique phenomenon.

Yesterday morning, while most eyes were still turned towards Chicago following ASCO, Micromet (MITI) managed to present another impressive set of clinical data in the picturesque town of Lugano, Switzerland. The data is from an ongoing phase I trial for the evaluation of the company’s lead product, MT103, in Non-Hodgkin’s Lymphoma [NHL], a trial which had already produced impressive results.
By  Ohad Hammer   (+23.96%  risk: moderate)  06/06/08 Comment


Get free stock alert for MITI:
Your Email Address:





People Bullish on MITI

Mikerun
Mike Havrilla
Principal
73%
5 mos ago

gregc
Analyst
N/A
6 mos ago

Dsc00126
scubongo
Sr. Analyst
73%
about 1 year ago

ice.patriot
Analyst
53%
about 1 year ago

bbbuskell2
Analyst
 3 %
about 1 year ago


People Bearish on MITI

bezede
Analyst
20%
about 1 year ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 377
2 Gerald Greene 18.14 +70.10% 208
3 stockmarketfunding.com 17.66 +25.70% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +75.30% 38


POPULAR STOCKS
Symbol Company Name Sentiment
MO Altria Group Inc
BAC Bank of America Corp
AMD Advanced Micro Devices Inc
POT Potash Corp. of Saskatchewan Inc.
AIG American International Group Inc.
GE General Electric Company

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on MITI


Discussion Wall + Add  
amritadas   (+0.00%)
A FREE report on upcoming FDA decision for small ca.. - FDA decision date coming up this month for small cap company's Pain drug. If the FDA approves the drug, the peak sales could reach over 200% of the com...
+   0 replies

amritadas   (+0.00%)
A FREE report on upcoming FDA decision for small ca.. - FDA decision date coming up this month for small cap company's Pain drug. If the FDA approves the drug, the peak sales could reach over 200% of the com...
+   0 replies


More Resources

Graphic_arrow1 About Micromet Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch